证券之星消息，9月12日医药商业板块较上一交易日下跌0.51%，百洋医药领跌。当日上证指数报收于 3883.69，上涨0.22%。深证成指报收于12996.38，上涨0.13%。医药商业板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 603716 | 塞力医疗 | 31.31 | 10.01% | 51.07万 | 15.56 Z | | 000078 | 海王生物 | 2.67 | 2.69% | 38.66万 | 1.02亿 | | 603108 | 润达医疗 | 11 17.14 | 1.30% | 13.77万 | 2.35亿 | | 600713 | 南京医药 | 5.08 | 0.99% | 17.73万 | 8986.88万 | | 002589 | 瑞康医药 | 2.96 | 0.68% | 21.33万 | 6270.06万 | | 600833 | 第一医药 | 13.66 | 0.44% | 5.75万 | 7851.33万 | | 000950 | ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 603716 | 塞力医疗 | 28.70 | 3.99% | 25.05万 | 7.19亿 | | 600538 | 国发股份 | 6.16 | 1.65% | 11.26万 | 6927.21万 | | 002462 | 第章章 | 14.09 | 1.22% | 3.56万 | 5007.96万 | | 000078 | 海于生物 | 2.62 | 1.16% | - 33.77万 | 8793.03万 | | 301015 | 百洋医药 | 31.29 | 0.84% | 9.83万 | 3.05亿 | | 600713 | 南京医药 | 5.01 | 0.80% | 15.62万 | 7796.73万 | | 301126 | 达嘉维康 | 11.92 | 0.68% | 2.86万 | 3420.67万 | | 000705 | 浙江震元 | 9.60 | 0.63% | 10.21万 | 9780.70万 | | 603122 | 合 ...

据证券之星公开数据整理，近期海王生物（000078）发布2025年中报。根据财报显示，海王生物净利润 同比下降30.23%。截至本报告期末，公司营业总收入143.12亿元，同比下降13.95%，归母净利润 3168.17万元，同比下降30.23%。按单季度数据看，第二季度营业总收入69.36亿元，同比下降18.82%， 第二季度归母净利润796.59万元，同比上升187.74%。 本次财报公布的各项数据指标表现不尽如人意。其中，毛利率9.31%，同比减7.48%，净利率0.45%，同 比减34.67%，销售费用、管理费用、财务费用总计12.44亿元，三费占营收比8.69%，同比增0.24%，每 股净资产0.7元，同比减37.23%，每股经营性现金流0.02元，同比减46.42%，每股收益0.01元，同比减 30.64% | 项目 | 2024年中报 | 2025年中报 | 同比增幅 | | --- | --- | --- | --- | | 营业总收入(元) | 166.31亿 | 143.12亿 | -13.95% | | 归母净利润(元) | 4540.98万 | 3168.17万 | -30.23% | ...

每经AI快讯，海王生物（SZ 000078，收盘价：2.58元）8月30日发布半年度业绩报告称，2025年上半年 营业收入约143.12亿元，同比减少13.95%；归属于上市公司股东的净利润约3168万元，同比减少 30.23%；基本每股收益0.012元，同比减少30.64%。 （记者 胡玲） 每经头条（nbdtoutiao）——近120个品牌、1600辆车逐鹿西南！下半年国内首个A级车展开幕：新能 源"第三极"将改写车市格局 ...

Group 1 - The company, Haiwang Biological, announced on August 29 that there are no overdue guarantees [1]

Core Viewpoint - Haiwang Bio (000078.SZ) reported a decline in revenue and net profit for the first half of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company achieved an operating revenue of 14.312 billion yuan, a year-on-year decrease of 13.95% [1] - The net profit attributable to shareholders was 31.6817 million yuan, down 30.23% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -70.5261 million yuan [1] - Basic earnings per share were 0.0120 yuan [1]

Core Viewpoint - Haiwang Bio has demonstrated steady performance with a revenue of 14.312 billion yuan and a net profit of 31.6817 million yuan in the first half of 2025, amidst significant changes in the pharmaceutical industry [1] Group 1: Full Industry Chain Layout - Haiwang Bio has established a complete "research-production-sales" industry chain over its 30 years in the pharmaceutical sector, enhancing its risk resistance and supporting continuous innovation [2] - The company has developed a vast pharmaceutical logistics network covering over 20 provinces in China, with 21 provincial logistics centers and 105 warehouses, improving service efficiency and customer satisfaction [2] - Haiwang Bio's product portfolio includes 505 approved drug registration numbers, covering large infusion products, Western medicine formulations, and traditional Chinese medicine, catering to diverse patient needs [2] Group 2: Innovation-Driven Growth - The company adheres to an innovation-driven development strategy, increasing R&D investment to foster new products and technologies [3] - During the reporting period, the innovative drug HW130 injection completed Phase I clinical research and initiated Phase II clinical production, while NEP018 received domestic clinical approval and began Phase I clinical sample production [3] - Haiwang Bio is actively exploring emerging fields such as biopharmaceuticals and high-margin generic drugs to create new profit growth points [3] Group 3: Digital Transformation - Haiwang Bio has made significant progress in digital transformation, with 102 subsidiaries implementing a financial shared service system, enhancing financial management and operational efficiency [4] - The digital transformation enables the company to respond more quickly to market changes, optimize resource allocation, and improve overall competitiveness [4] - The company plans to continue its innovation-driven strategy, deepen its full industry chain layout, and enhance digital transformation and intelligent upgrades to maintain steady growth in the pharmaceutical distribution industry [4]

深圳市海王生物工程股份有限公司 2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 编制单位：深圳市海王生物工程股份有限公司 单位：万元 | | | 占用方与上 | 上市公司核 | 2025 年期 | 2025 年半年度 | 2025 年半年 | 2025 年半年 | 2025 年半年 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性 资金占用 | 资金占用方名 称 | 市公司的关 | 算的会计科 | 初往来资 | 往来累计发生 金额（不含利 | 度往来资金 的利息（如 | 度偿还累计 | 度期末往来 | 占用形成 原因 | 占用性质 | | | | 联关系 | 目 | 金余额 | | | 发生金额 | 资金余额 | | | | | | | | | 息） | 有） | | | | | | 现控股股 | | | | | | | | | | | | 东、实际 | | | | | | | | | | | | 控制人及 | | | | | | | | | | | | 其附属企 | | | | | ...

深圳市海王生物工程股份有限公司 2025 年半年度财务报告 单位：元 | 项目 | 期末余额 | 期初余额 | | --- | --- | --- | | 流动资产： | | | | 货币资金 | 3,063,948,201.93 | 3,456,273,633.71 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | 122,630,346.17 | 125,433,276.07 | | 衍生金融资产 | | | | 应收票据 | 810,849,804.04 | 900,426,597.57 | | 应收账款 | 15,147,853,611.67 | 15,319,422,562.26 | | 应收款项融资 | 59,132,839.22 | 164,791,057.77 | | 预付款项 | 350,382,156.91 | 317,289,075.05 | | 应收保费 | | | | 应收分保账款 | | | | 应收分保合同准备金 | | | | 其他应收款 | 1,775,293,809.31 | 1,822,982,141.21 | | 其中：应收利息 | | ...

证券代码：000078 证券简称：海王生物 公告编号：2025-050 深圳市海王生物工程股份有限公司 关于为控股子公司提供担保实施情况的公告 本公司及董事局全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 一、担保情况概述 为支持子公司业务发展，深圳市海王生物工程股份有限公司（以下简称"公 司"或"本公司"）于2025年3月31日召开的第九届董事局第二十二次会议、2025年 4月18日召开的2025年第一次临时股东大会，审议通过了为控股子公司提供担保 等事项，担保决议有效期为自公司股东大会审议通过该议案之日起一年。担保事 项均已提请公司股东大会授权管理层，根据银行审批情况协商签订担保协议、办 理相关担保手续；具体情况请参见公司2025年4月1日、2025年4月19日刊登在《证 券时报》《上海证券报》《中国证券报》《证券日报》及巨潮资讯网上的相关公 告。 在上述股东大会审批范围内，公司近期为以下子公司向银行或其他金融机构 申请综合授信额度等事项提供了担保： 1、浙江海王数据服务有限公司（以下简称"浙江海王"）向上海浦东发展银 行股份有限公司杭州分行申请综合授信额度，公司为其在 ...